GENFIT begins phase 3 trial of elafibranor in primary biliary cholangitis
GENFIT has started the phase 3 ELATIVE clinical trial for evaluating the efficacy and safety of elafibranor for the treatment of primary biliary cholangitis (PBC). According to the French pharma company, ELATIVE is a randomized, double blind, placebo-controlled, global multicenter phase 3 study. Elafibranor is a dual PPAR alpha and delta agonist in primary biliary […]